Evaluating the efficacy, safety, tolerability of use and treatment adherence in two different dosing schedules, pre-costagionale and costagionale, of a sublingual allergoid (Lais Parietaria)administered to patients suffered from oculorhinitis with or without bronchial asthma by Parietaria. Randomized double-blind, multicenter, parallel group, placebo-controlled.
Latest Information Update: 31 Oct 2011
At a glance
- Drugs Parietaria pollen allergy immunotherapy (Primary)
- Indications Asthma; Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Lofarma S.p.A
Most Recent Events
- 06 Aug 2011 New trial record